Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.

Belimumab (brand name Benlysta) is used to treat active systemic lupus erythematosus (SLE) or active lupus nephritis (lupus-related kidney inflammation) in adults and children 5 years of age and older. Belimumab is given with other lupus medicines.

Nov 8, 2024 · Benlysta (belimumab) is used to treat adults and children aged 5 years and older (weighing at least 15 kg) with active systemic lupus erythematosus (SLE) when used with standard therapy active lupus nephritis (lupus-related kidney inflammation) patients when used with standard therapy.

Belimumab (Benlysta ®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE).

Belimumab is a synthetic (man-made) injectable antibody that reduces the activity of immune cells called B-cells in patients with systemic lupus erythematosus (SLE). SLE is an inflammatory autoimmune disease, which means that the body's immune system attacks its own tissues and causes inflammation.

Belimumab is used with other medications to treat certain types of systemic lupus erythematosus (SLE or lupus; an autoimmune disease in which the immune system attacks healthy parts of the body such as joints, skin, blood vessels, and organs) in adults and children 5 …

Belimumab is a fully human IgG1λ recombinant monoclonal antibody directed against BLyS. Specific binding of belimumab with the soluble BLyS prevents the interaction of BLys with its three receptors and indirectly decreases the B-cell survival and production of …

Feb 1, 2025 · Belimumab injection is used to treat active, autoantibody-positive, systemic lupus erythematosus (SLE) and active lupus nephritis in patients who are also receiving other lupus treatments. It is a monoclonal antibody that changes the immune system to …

Belimumab, the first biologic approved for the treatment of systemic lupus erythematosus (SLE), has been shown to reduce autoantibody levels in people with SLE and help control disease activity. To assess the benefits and harms of belimumab (alone ...

Belimumab (Benlysta) is approved for adults and children with lupus and lupus nephritis. Learn how it works to reduce the inflammation caused by lupus.